Clinical Insights: January 18, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Rykindo® (risperidone) for Extended-Release Injectable Suspension – New Drug Approval – January 13, 2023 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing…
Clinical Insights: January 11, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Leqembi™ (lecanemab-irmb) Injection New Drug Approval – January 6, 2023 – The U.S. Food and Drug Administration approved Leqembi™ (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of…
Clinical Insights: December 28, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Sunlenca® (lenacapavir) – New Drug Approval – December 22, 2022 – Gilead Sciences, Inc. announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by…
Clinical Insights: December 21, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Adstiladrin® (nadofaragene firadenovec-vncg) – New Drug Approval – December 16, 2022 – The U.S. Food and Drug Administration approved Adstiladrin® (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells)…
Clinical Insights: December 14th, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage December 09, 2022 Methylphenidate Hydrochloride Extended Release Tablets (Discontinuation) December 08, 2022 Etodolac Tablets (Discontinuation) Promethazine Tablets…
Clinical Insights: December 7, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Rezlidhia™ (olutasidenib) Capsules – New Drug Approval – December 1, 2022 – The Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia™) capsules for adult patients with relapsed or refractory…
Clinical Insights: November 30, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Hemgenix™ (etranacogene dezaparvovec-drlb) Suspension for Intravenous Infusion – New Drug Approval – November 22, 2022 – The U.S. Food and Drug Administration approved Hemgenix™ (etranacogene dezaparvovec), an adeno-associated virus…
Clinical Insights: November 23, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Tzield™ (teplizumab-mzwv) – New Drug Approval – November 18, 2022 – The U.S. Food and Drug Administration approved Tzield™ (teplizumab-mzwv) injection to delay the onset of stage 3 type…
Clinical Insights: November 16, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Elahere™ (mirvetuximab soravtansine-gynx) Injection – New Drug Approval – November 14, 2022 – The Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere™, ImmunoGen, Inc.) for adult…
Clinical Insights: November 9, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage November 08, 2022 Glucagon Injection (Discontinuation) Hydrochlorothiazide and Spironolactone (Aldactazide) Tablets (Discontinuation) November 02, 2022 Butenafine Hydrochloride…
Clinical Insights: November 2, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Tecvayli™ (teclistamab-cqyv) Injection – New Drug Approval – October 25, 2022 – The Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli™, Janssen Biotech, Inc.), the first bispecific B-cell…
Clinical Insights: October 26, 2022
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Imjudo® (tremelimumab-actl) Injection – New Drug Approval – October 24, 2022 – AstraZeneca’s Imjudo® (tremelimumab) in combination with Imfinzi® (durvalumab) has been approved in the US for the treatment…